Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Neurology

Which Pharma Companies are going to Transform t...

Post Traumatic Stress Disorder (PTSD) is a " complex physical, cognitive, emotional, and behavioral consequences of psychological trauma." It is characterized by intrusive thoughts, nightmares, fla...

May 06, 2022

Pharma News and Updates for AstraZeneca, Supernus, and BMS
VBL Therapeutics’ VB-111 (ofranergene obadenovec); BMS’s mavacamten (Camzyos); Merck’s KEYTRUDA; AstraZeneca and Daiichi’s Enhertu; Pfizer/Biohaven’s VYDURA (rimegepant); AstraZeneca’s Ultomiris; Supernus’s Viloxazine (Qlebree); AbbVie’s Rinvoq

FDA Grants Fast Track Designation to VB-111 for Platinium-resistant Ovarian Cancer The FDA has given VBL Therapeutics’ VB-111 (ofranergene obadenovec), a targeted anticancer viral gene therapy, fast track designation for use as a viable therapeutic option in patients with platinum-resistant Ovarian Cancer. VB...

Find More
Organ on a Chip Market Trends and Developments
Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated structures and functions associated with the living human organs. The microdevices are composed of a clear flexible polymer that is almost the size of a USB memory stick and comprises hollow microfluidic channels lined up with l...

Find More
Pharma News and Updates for Coherus, Keymed, Roche, Vicore, Cassiopea
Coherus Biosciences’ Toripalimab; Keymed’s CMG901; Biogen Alzheimer’s Drug Aduhelm; Vicore’s Digital Therapeutics Study; Cassiopea’s Acne Treatment Winlevi; Samsung Biologics Acquires Samsung Bioepis; Roche’s Giredestrant; Ashai Kasei Acquires Bionova

FDA Grants Orphan Drug Designation to Coherus Biosciences’ Toripalimab for Small Cell Lung Cancer The FDA granted orphan drug status to Coherus Biosciences’ Toripalimab (TuoYi) based on data from the phase 3 JUPITER-08 study in patients with extensive-stage Small-cell Lung Cancer (ES-SCLC). Patients in the curre...

Find More

More Views & Analysis

bispecific-antibodies
Rise In Bispecific Antibodies Utilization As Antibody Therapeutics

Bispecific Antibodies (BsAbs) are antibodies that contain two different antigens or have two different epitopes on the same antigen. It is observed for Bispecific Antibodies in clinical trials that the therapeutic effects of these are considerably higher than those of monoclonal antibodies (MoAbs). There are a vast...

Find More

MedTech News and Updates for Penumbra, Axonics, Stimwave, SonoScape
Penumbra’s Indigo System; Axonics’s F15 Recharge-free SNS; Stimwave’s FREEDOM-1 Clinical Trial; Virtual Incision’s MIRA Platform; SonoScape’s HD-550 Endoscopy system; SMART Medical’s G-EYE Colonoscope Series

Penumbra launched the Indigo® System with Lightning™ 7 and Lightning 12 Intelligent Aspiration in Europe On April 14, 2022, Penumbra, Inc., a leading medical device company focused on developing innovative therapies for neuro and vascular conditions, received the CE mark for its Indigo Aspiration System w...

Find More

Metaverse in Healthcare Segment
How Metaverse is Set to Transform the Healthcare Dynamics?

The metaverse, or Internet 3.0, is an evolution of how individuals can socially connect with each other despite geographical distance and regional boundaries. Metaverse is set to bring a disruptive revolution in various aspects of life, including healthcare. For many decades, the delivery of healthcare has required...

Find More

Pharma News and Updates BioXcel, Eton, Gilead, Pfizer, Alembic, Telix
BioXcel’s Agitation Drug Igalmi; FDA Approves Cysteine Hydrochloride Injection; Gilead’s Trodelvy; Alembic Pharma’s Topical Anesthetic Cream; Pfizer Acquires ReViral; Telix Buys Lilly’s Failed Cancer Drug Lartruvo

FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Disorder. Igalmi (dexmedetomidine) is the first drug approved for this application that comes in the form of a tablet that...

Find More

Pharma News and Updates Precigen, Biogen, Cerevance, Sanofi, Clovis
Precigen’s PRGN-3006; Yescarta Approved as a First CAR T-cell Therapy for R/R LBCL; Biogen & Ionis’ BIIB078; Nobelpharma’s HYFTOR (sirolimus topical gel) 0.2%; Cerevance Parkinson’s Drug; Sanofi & Regeneron’s Dupixent; Clovis’s Rubraca for Ovarian Cancer; Immunocore Eye Cancer Cell Therapy Approval

FDA Approves Yescarta as a First CAR T-cell Therapy for Initial Treatment of R/R Large B-cell Lymphoma Until now, existing CAR-T therapies have been reserved for patients with blood cancer who have tried multiple treatments. The FDA has approved Yescarta, a CD19-directed CAR-T therapy developed by Gilead Science...

Find More

MedTech News for Ypsomed Fresenius Kabi Sientra Synchron HLT
Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies

Ypsomed Collaborated with CamDiab for Smartphone-based Automated Insulin Delivery On March 22, 2022, Ypsomed, a leading manufacturer of injection and infusion systems for self-medication partnered with CamDiab Ltd, developer of CamAPS FX, an app for the management of glucose levels via insulin pumps using an ada...

Find More

Immune thrombocytopenic purpura (ITP) is a disorder that results in the immune system killing its pl.....

Find More

The first biosimilar was made available to patients in the United States six years ago in 2021. Thes.....

Find More

Soft Tissue Sarcoma (STS) tumors constitute 1% of all the malignancies. These are rare neoplasms tha.....

Find More

An autoimmune disease in which the immune system attacks its healthy skin, Cutaneous Lupus Erythemat.....

Find More

Nestlé and Unilever are multinational corporations established in 1866 and 1930, respectively. The .....

Find More

The gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....

Find More